Acquired in 2014 from the Anglo-Saxon Group GSK, the Aspen Group has already made a wave of investment in recent years to increase capacity and host new products (new buildings including a quality control laboratory, new sterile filling lines and modernisation of the packaging plant).The international Aspen group wishes to continue its investment and diversification strategy for the Normand site, notably by relocating the production of anesthetics currently manufactured abroad (including Australia) to a third party partner. These productions, which should eventually be transferred to Notre Dame de Bondeville, represent 48 million units of injectable anaesthetic drugs each year and must generate the hiring of 100 new employees.For a new building, inaugurated in June 2019, it is now a real critical phase of re-industrialisation that is being played in Notre-Dame-de-Bondeville: The ODINEn project effects, over the next 3 years, this new step aims to invest EUR 19 m in new production technologies for the start of commercial production of anesthetics by mid-2022 at the latest. Why the Normandie site?The Normandie site is proposed for its expertise, its potential, its environment and its location in Europe as a candidate for the installation of these new production technologies in a context of strong competition between the internal industrial sites of Aspen (the South African site in Port Elisabeth, as well as the site of Bad-Oldesloe in Germany being also on the list of sites eligible for these productions).